on Theranexus (EPA:ALTHX)
Half-Yearly Review of the Theranexus Liquidity Contract
Biopharmaceutical company Theranexus, which specializes in the treatment of rare neurological diseases, has published the half-yearly results of its liquidity agreement with Portzamparc. As of June 30, 2025, the liquidity account showed 41,770 Theranexus shares and €31,202.02. In comparison, the balance sheet as of December 31, 2024, showed 110,572 shares and €36,223.69.
A withdrawal of 50,000 euros took place on March 6, 2025. During the first half of 2025, 67,331 shares were purchased for 54,017.33 euros through 207 transactions, while 136,133 shares were sold for 98,995.66 euros through 271 transactions.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Theranexus news